Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Caladrius Biosciences Q2 EPS $(0.11) Misses $(0.10) Estimate

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent decrease over losses of $(0.10) per share from
byBill Haddad
August 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent decrease over losses of $(0.10) per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

EXCLUSIVE: Genius Brands’ POW! Entertainment Venture Signs 20-Year Deal With Disney’s Marvel Studios To License Name, Likeness Of Stan Lee For Future Feature Films, TV Productions, Disney Theme Parks, Experiences, No Terms Disclosed

By Benzinga Newsdesk
Today, 11:26 PM
Beverly Hills, CA -- May 18, 2022 – “Stan Lee Universe, LLC” Genius Brands International’s “Genius Brands” (NASDAQ: GNUS) venture with POW! Entertainment, has signed a 20-year deal withBeverly Hills, CA -- May 18, 2022 – “Stan Lee Universe, LLC” Genius

DIS